We recently published a list of the 13 Most Undervalued Blue Chip Stocks To Buy According To Analysts. In this article, we ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

The decision, which the U.S. Court of Appeals for the Third Circuit said was a close call, hinged on whether an informal ...

A U.S. appeals court has reinstated more than 500 lawsuits against drugmaker Merck & Co. because of its osteoporosis drug Fosamax, which plaintiffs allege increases risk of thigh bone fractures, ...

More than 500 lawsuits, which a U.S. appeals court revived on Friday, allege Merck & Co. failed to warn patients that its osteoporosis drug Fosamax raised the risk of thigh bone fractures. Separately, ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...